COMPANY PROFILE

 RegionCampania
 StatusSME

 
 PROPOSAL 

Title A new marker for a prognosis of prostate cancer
Project id.43
Reference sectorBIOTECHNOLOGY
IP Protection Level“PEPTIDIC AND NON PEPTIDIC LIGANDS FOR IMMUNODETECTION OF THE RECEPTOR FOR UROTENSIN II" Patent granted n. 12194425.0-1410/2592092
Description of the innovation projectWe set up an Italian limited company in 2009, Pharma Bullet Ltd., which has an international license of the patent of the "prognostic marker of prostate cancer (“immunohistochemistry technology”). The patent is owned by researchers and university professors. The patent is referring to prognostic method for the human prostatic adenocarcinoma, granted in Italy and Europe and pending around the world (USA, Russia, etc.). Kit in vitro for the prognosis of the prostate cancer, including antibodies and reagents to be used on the cancer prostate biopsies to assess the prognosis. This product was manufactured, being to be validated (the clinical validation is achieved)
State of dev.Product
Industrial applicationBiotech, Medical device
Market segmentCustomers: Hospitals, clinics, diagnostic centers (urology and anatomical pathology). Market: international.
Advantage factorThe only product in the world which discriminates the aggressiveness of the prostate cancer and allows to do the prostate cancer prognosis.
Commercial challengeDirect competitors (products with the same output clinical) = None
Publications and Customer Refereces“JOURNAL OF CELLULAR BIOCHEMISTRY” 112:341–353 (2011) “Urotensin-II Receptor predicts the clinical outcome of Prostate Cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells” “Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in the prostate cancer.”“FUTURE ONCOLOGY” 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18.

Proposal of cooperation agreementCommercial representative, Venture capital financing, Distribution Agreement